Publications

Poster: RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

ESMO TAT 2023 Congress

^{6-8 March 2023, Paris}

Poster: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer

ESMO 2022 Congress

^{9-13 September 2022, Paris}